Ketamine IV for the prevention of depression in the elderly: new data

Published Date: 13 Mar 2023

Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.

Read Full News

Latest News

Pediatric Ketamine Sedation Not Tied to Serious AEs

Children receiving ketamine sedation in the ED rarely have serious side effects, but risks are slightly higher in those who are older, those with respiratory infections, or those receiving opioids.

NICE Recommends Mepolizumab for Uncontrolled COPD

Mepolizumab is the second biologic approved for eosinophilic COPD this year, joining dupilumab in offering an alternative to triple therapy alone.

Diabetic Ketoacidosis Diagnosed Beyond Lab Criteria

Not all patients in the emergency department diagnosed with diabetic ketoacidosis meet laboratory criteria; a study shows that physicians rely on clinical signs and symptoms.

Older Age Tied to Higher CT Positivity in Abdominal Pain

Older adults visiting the emergency department for abdominal pain have higher risks for CT positivity and hospital admission than younger adults, despite less specific symptoms.

Texas Firearm Injuries: ED Admits Up, Costs Nearly Double

Firearm injuries continue to strain Texas emergency departments, with increasing hospitalizations and nearly doubled charges underscoring the growing burden on healthcare systems and communities.

AI Decision Support in ED: Helpful Tool or Clinical Risk?

Research shows artificial intelligence has use in the emergency department, but how it’s implemented is key.

Todays Updates

Psychotropics Linked to Increased BMI, CVD Risk

Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Todays Updates

Psychotropics Linked to Increased BMI, CVD Risk

Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Latest News

Children receiving ketamine sedation in the ED rarely have serious side effects, but risks are slightly higher in those who are older, those with respiratory infections, or those receiving opioids.

Mepolizumab is the second biologic approved for eosinophilic COPD this year, joining dupilumab in offering an alternative to triple therapy alone.

Not all patients in the emergency department diagnosed with diabetic ketoacidosis meet laboratory criteria; a study shows that physicians rely on clinical signs and symptoms.

Older adults visiting the emergency department for abdominal pain have higher risks for CT positivity and hospital admission than younger adults, despite less specific symptoms.

Firearm injuries continue to strain Texas emergency departments, with increasing hospitalizations and nearly doubled charges underscoring the growing burden on healthcare systems and communities.

Research shows artificial intelligence has use in the emergency department, but how it’s implemented is key.

News All Time

Can Rise of Direct Primary Care Ease Hospital Admissions?

Research has shown direct care may reduce emergency department visit and hospital use, but questions remain about equity.

US Kratom Use Surges 65-Fold in 13 Years

US Kratom use increased more than 65-fold from 2010 to 2023, with a lower incidence of adverse outcomes in states that banned the substance, new research shows.

Hydronephrosis on USG Predicts Stones but May Not Cut CT Use

Hydronephrosis identified on point-of-care ultrasound is linked to higher risks for stone disease and early urologic intervention in suspected renal colic but not with reduced CT use or ED stays.

Apnimed's Sleep Apnea Pill Meets Main Goal in Late-stage Study

Privately held biotech firm Apnimed said on Monday its experimental pill for a sleep disorder met the main ⁠goal in a late-stage trial, potentially offering a convenient...

Hidradenitis Suppurativa Tied to Higher Cardiovascular Risks

Individuals with HS show higher risks for cardiovascular outcomes, including hypertension, coronary or ischemic heart disease, venous thromboembolism, and myocardial infarction, in a meta-analysis.

African Public Health Agency Announces New Ebola Outbreak in Congo, 65 Suspected Deaths

Africa's top public health agency said on Friday that there was a confirmed Ebola outbreak in Democratic Republic of Congo's Ituri province, with 65 deaths out of 246...

Rapid Susceptibility Test Falls Short in Bacteremia

Rapid antimicrobial susceptibility testing of blood cultures is not superior to standard testing in patients with gram-negative bloodstream infections, according to the FAST trial.

Socioeconomic Gaps Tied to Concussion-Related ED Visits

Socioeconomic disparities determine where patients seek concussion care and patients' likelihood of receiving follow-up care, a study finds.

Balanced Fluid: No Renal Benefit Over Saline in Septic Shock

In children with septic shock, choosing balanced fluid over saline does not appear to change short-term kidney outcomes or survival.

Is Telemedicine Comparable to In-Person Neurology Care?

Virtual neurology care for new patients is comparable to in-person care, with similar 90-day follow-up rates, ED visits, and hospitalizations, a new study shows.

Regenxbio Shares Sink as Safety Concerns Overshadow Muscle Disorder Therapy Trial Win

Regenxbio said on Thursday that its experimental gene therapy for a muscle-wasting disorder met the main goal ⁠in a late-stage study, but its shares plunged 31% in morning...

US Drug Overdose Deaths Dropped for Third Straight Year in 2025, CDC Data Shows

Drug overdose deaths in the United States fell nearly ⁠14% in 2025, federal estimates showed on Wednesday, marking a third ⁠consecutive year of declines.

Common Practice of DOAC Switching After Stroke Challenged

A multicenter, registry-based cohort study showed no short-term benefit of the common practice of switching anticoagulants after a breakthrough ischemic stroke in patients with atrial fibrillation.

Resistant Gut Bacteria May Flag C difficile Infection Risk

Adults colonised with extended-spectrum beta-lactamase-producing bacteria in the intestinal tract may face higher odds of developing Clostridioides difficile infection.

High-Risk Mental Health Patients Left Unmonitored in A&E

A 3-year RCEM programme finds high-risk mental health patients in emergency departments are going unmonitored — though rates have improved significantly since 2023.

Scotland Clears New Bladder Cancer Combination Therapy

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

Recommended News For You

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

Scientists develop scans that light up aggressive cancer tumors for better treatment

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Older Adults With Advanced Cancer Prioritize Quality of Life

Researchers discuss HER2-low and HER2-zero in breast cancer

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

Three out of ten breast cancers detected between screenings, study finds

Recommended Articles For You

The Pros and Cons of Steroid Therapy for ITP 

AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology 

Survival Rate Dynamics in Hematologic and Solid Malignancies 

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

FDA approves rivanetin as the first-line treatment for lung cancer.

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

New First-Line Option for Advanced ALK-Positive Lung Cancer

5.

Certain surgical gestures during prostate removal linked to better sexual function recovery

1.

Tremelimumab: A Potential Breakthrough in Cancer Treatment

2.

The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy

3.

Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review

4.

Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics

5.

Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

3.

Updates on Standard V/S High Risk Myeloma Treatment

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot